REFERENCES
- Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008;372:657–68.
- McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest 2008;133:507–16.
- Krueger DA, Franz DN. Current management of tuberous sclerosis complex. Paediatr Drugs 2008;10: 299–313.
- Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010;35:14–26.
- Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: Characteristics of 230 patients at enrollment. Am J Resp Crit Care Med 2006;173:105–11.
- McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364:1595–606.
- Neurohr C, Hoffmann AL, Huppmann P, et al. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?Respir Res 2011;12:66.
- Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Int Med 2011;154:797–805.
- Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clinic Proc 1991;66:792–6.
- Matsui K, Takeda K, Yu ZX, et al. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study.Am J Resp Crit Care Med 2000;161: 1002–9.
- Wilson AM, Slack HL, Soosay SA, et al. Lymphangioleiomyomatosis. A series of three case reports illustrating the link with high oestrogen states. Scott Med J 2001;46:150–2.
- Yano S. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment. Thorax 2002;57:1085–6.
- Oberstein EM, Fleming LE, Gomez-Marin O, Glassberg MK. Pulmonary lymphangioleiomyomatosis (LAM): Examining oral contraceptive pills and the onset of disease. J Womens Health 2003;12:81–5.
- Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med 1990;323:1254–60.
- Reddy DS. Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. Expert Rev Clin Pharmacol 2010;3: 183–92.
- Jozwiak S, Schwartz RA, Janniger CK, et al. Skin lesions in children with tuberous sclerosis complex: Their prevalence, natural course, and diagnostic significance. Int J Dermatol 1998;37:911–7.
- Rakowski SK, Winterkorn EB, Paul E, et al. Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int 2006;70: 1777–82.
- Joinson C, O’Callaghan FJ, Osborne JP, et al. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med 2003;33:335–44.
- Gorenoi V, Schönermark MP, Hagen A. Nutzen und Risiken hormonaler Kontrazeptiva bei Frauen. Cologne: Deutsches Institut für Medizinische Dokumentation und Information (DIMDI) 2007. [In German]
- Wahedna I, Cooper S, Williams J, et al. Relation of pulmonary lymphangio-leiomyomatosis to use of the oral contraceptive pill and fertility in the UK: A national case control study. Thorax 1994;49:910–4.
- Franz DN, Brody A, Meyer C, et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Resp Crit Care Med 2001;164:661–8.
- French JA, Pedley TA. Clinical practice. Initial management of epilepsy. N Engl J Med 2008;359: 166–76.
- El-Hashemite N, Walker V, Kwiatkowski DJ. Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: A tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Cancer Res 2005;65: 2474–81.
- Gould Rothberg BE, Grooms MC, Dharnidharka VR. Rapid growth of a kidney angiomyolipoma after initiation of oral contraceptive therapy. Obstet Gynecol 2006;108:734–6.